JP2017505822A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505822A5 JP2017505822A5 JP2016569114A JP2016569114A JP2017505822A5 JP 2017505822 A5 JP2017505822 A5 JP 2017505822A5 JP 2016569114 A JP2016569114 A JP 2016569114A JP 2016569114 A JP2016569114 A JP 2016569114A JP 2017505822 A5 JP2017505822 A5 JP 2017505822A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- psoriasis
- pharmaceutically acceptable
- complex according
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP1400075 | 2014-02-14 | ||
| HU1400075A HUP1400075A2 (hu) | 2014-02-14 | 2014-02-14 | Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói |
| PCT/IB2015/051086 WO2015121836A1 (en) | 2014-02-14 | 2015-02-13 | Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017505822A JP2017505822A (ja) | 2017-02-23 |
| JP2017505822A5 true JP2017505822A5 (enExample) | 2018-04-05 |
| JP6445591B2 JP6445591B2 (ja) | 2018-12-26 |
Family
ID=89991398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569114A Expired - Fee Related JP6445591B2 (ja) | 2014-02-14 | 2015-02-13 | シロリムス及びその誘導体の複合体、それらの調製方法ならびにそれらを含有する医薬組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20170165237A1 (enExample) |
| EP (1) | EP3104844B1 (enExample) |
| JP (1) | JP6445591B2 (enExample) |
| CN (1) | CN106456780A (enExample) |
| AU (1) | AU2015216631B2 (enExample) |
| CA (1) | CA2939602A1 (enExample) |
| ES (1) | ES2784843T3 (enExample) |
| HK (1) | HK1231416A1 (enExample) |
| HU (2) | HUP1400075A2 (enExample) |
| IL (1) | IL247239A0 (enExample) |
| PL (1) | PL3104844T3 (enExample) |
| RU (1) | RU2016136697A (enExample) |
| UA (1) | UA120508C2 (enExample) |
| WO (1) | WO2015121836A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008063563A2 (en) | 2006-11-16 | 2008-05-29 | Transderm, Inc. | Methods of treating keratin hyperproliferation disorders using mtor inhibitors |
| US10172789B2 (en) | 2013-01-24 | 2019-01-08 | Palvella Therapeutics Llc | Compositions for transdermal delivery of mTOR inhibitors |
| HUP1600271A2 (hu) * | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei |
| HUP1600270A2 (hu) * | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Ivacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadott készítményei |
| HUP1600269A2 (hu) * | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Lumacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyászati készítményei |
| US10383865B2 (en) | 2016-04-25 | 2019-08-20 | Druggability Technologies Ip Holdco Limited | Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them |
| US10376501B2 (en) | 2016-04-25 | 2019-08-13 | Druggability Technologies Ip Holdco Limited | Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| CA3032473A1 (en) * | 2016-08-10 | 2018-02-15 | The Board Of Regents Of The University Of Texas System | Topical rapamycin therapy |
| EP3565520A4 (en) | 2017-01-06 | 2020-08-19 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE |
| JP7376361B2 (ja) * | 2017-03-07 | 2023-11-08 | エフ． ホフマン－ラ ロシュ アーゲー | 免疫調節マクロライドのための安定な配合物 |
| WO2020010073A1 (en) * | 2018-07-02 | 2020-01-09 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE |
| AU2020226527A1 (en) * | 2019-02-20 | 2021-10-14 | AI Therapeutics, Inc. | Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders |
| AU2020277132B1 (en) * | 2020-11-24 | 2021-11-04 | Aft Pharmaceuticals Limited | A Rapamycin Composition |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4826689A (en) | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
| JPH04501817A (ja) | 1989-06-05 | 1992-04-02 | デルフ エリック ウィリアム | 身体の鍛練装置に関する改良 |
| US5286730A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
| ZA935110B (en) | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
| CH686761A5 (de) | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
| GB9601120D0 (en) | 1996-01-19 | 1996-03-20 | Sandoz Ltd | Organic compounds |
| CA2230748C (en) | 1997-03-14 | 2010-08-03 | American Home Products Corporation | Rapamycin formulations for oral administration |
| GB9723669D0 (en) | 1997-11-07 | 1998-01-07 | Univ Aberdeen | Skin penetration enhancing components |
| US8236048B2 (en) | 2000-05-12 | 2012-08-07 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
| US20030054042A1 (en) | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
| GB0126253D0 (en) | 2001-10-31 | 2002-01-02 | Metris Therapeutics Ltd | Treatment method |
| US7083802B2 (en) | 2003-07-31 | 2006-08-01 | Advanced Ocular Systems Limited | Treatment of ocular disease |
| AR045957A1 (es) | 2003-10-03 | 2005-11-16 | Novartis Ag | Composicion farmaceutica y combinacion |
| AR050374A1 (es) | 2004-08-20 | 2006-10-18 | Wyeth Corp | Forma polimorfica de rafampicina |
| BRPI0607198A2 (pt) * | 2005-02-15 | 2016-11-01 | Wyeth Corp | composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica |
| AU2006222409A1 (en) * | 2005-03-08 | 2006-09-14 | Lifecycle Pharma A/S | Pharmaceutical compositions comprising sirolimus and/or an analogue thereof |
| BRPI0606282A2 (pt) | 2005-03-17 | 2009-06-09 | Elan Pharma Int Ltd | composições injetáveis de compostos imunossupressores em nanopartìculas |
| AU2006235538A1 (en) | 2005-04-12 | 2006-10-19 | Wisconsin Alumni Research Foundation | Micelle composition of polymer and passenger drug |
| WO2006123226A2 (en) | 2005-05-18 | 2006-11-23 | De Villiers, Malan | An inhibitor of mtor for inhibiting the formation of scar tissue |
| US20070048350A1 (en) * | 2005-08-31 | 2007-03-01 | Robert Falotico | Antithrombotic coating for drug eluting medical devices |
| BRPI0600285C1 (pt) | 2006-01-13 | 2011-10-11 | Brz Biotecnologia Ltda | compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas |
| GB0602632D0 (en) | 2006-02-08 | 2006-03-22 | Pliva Istrazivacki Inst D O O | Preparation Of A Solid Dosage From Comprising Tacrolimus And/Or Sirolimus |
| US7812032B2 (en) | 2006-07-25 | 2010-10-12 | Abbott Laboratories | Crystalline forms of rapamycin analogs |
| CN1919194A (zh) | 2006-08-17 | 2007-02-28 | 刘瑜玲 | 西罗莫司的液体组合物 |
| US20080138405A1 (en) | 2006-12-06 | 2008-06-12 | Raheja Praveen | Sirolimus nanodispersion |
| EP1952807A1 (en) * | 2007-01-24 | 2008-08-06 | LEK Pharmaceuticals D.D. | Sirolimus formulation |
| KR20090118999A (ko) | 2007-03-07 | 2009-11-18 | 아브락시스 바이오사이언스, 엘엘씨 | 항암제로서 라파마이신 및 알부민을 포함하는 나노입자 |
| US20090130210A1 (en) | 2007-09-11 | 2009-05-21 | Raheja Praveen | Pharmaceutical compositions of sirolimus |
| US20090068266A1 (en) | 2007-09-11 | 2009-03-12 | Raheja Praveen | Sirolimus having specific particle size and pharmaceutical compositions thereof |
| HU230862B1 (hu) | 2008-04-28 | 2018-10-29 | DARHOLDING Vagyonkezelő Kft | Berendezés és eljárás nanorészecskék folyamatos üzemű előállítására |
| US20100098770A1 (en) | 2008-10-16 | 2010-04-22 | Manikandan Ramalingam | Sirolimus pharmaceutical formulations |
| GB0908129D0 (en) | 2009-05-12 | 2009-06-24 | Innovata Ltd | Composition |
| EP2442793A1 (en) | 2009-06-19 | 2012-04-25 | Nanoform Hungary Ltd. | Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them |
| HUP0900384A2 (en) | 2009-06-19 | 2011-01-28 | Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag | Nanoparticulate olmesartan medoxomil compositions |
| HUP0900376A2 (en) | 2009-06-19 | 2011-01-28 | Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag | Nanoparticulate candesartan cilexetil composition |
| AU2010261509A1 (en) | 2009-06-19 | 2012-02-09 | Nanoform Hungary Ltd. | Nanoparticulate telmisartan compositions and process for the preparation thereof |
| KR101721281B1 (ko) | 2009-09-25 | 2017-04-10 | 위스콘신 얼럼나이 리서어치 화운데이션 | 치료제의 미셀 캡슐화 |
| KR101267813B1 (ko) | 2009-12-30 | 2013-06-04 | 주식회사 삼양바이오팜 | 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물 |
| WO2011128910A2 (en) | 2010-03-02 | 2011-10-20 | Rpg Life Sciences Limited | A drug delivery solid dosage formulation of sirolimus |
| US9101541B2 (en) | 2010-04-28 | 2015-08-11 | Cadila Healthcare Limited | Stable solid pharmaceutical matrix compositions of sirolimus |
| EP2575889B1 (en) | 2010-06-02 | 2015-04-22 | Fresenius Kabi Oncology Ltd | Stable pharmaceutical compositions of rapamycin esters |
| HUP1000325A2 (en) | 2010-06-18 | 2012-01-30 | Druggability Technologies Ip Holdco Jersey Ltd | Nanostructured aprepitant compositions and process for their preparation |
| US20120022095A1 (en) | 2010-06-24 | 2012-01-26 | Teng Joyce M C | Topical rapamycin for treatment of facial angiofibromas in tuberous sclerosis |
| IT1400977B1 (it) | 2010-07-01 | 2013-07-05 | Euticals Spa | Nuovi complessi di inclusione farmaceutici, solidi, solubili in acqua e le loro soluzioni acquose per uso orale, oftalmico, topico o parenterale, contenenti un macrolide ed alcune ciclodestrine. |
| WO2012142145A1 (en) | 2011-04-12 | 2012-10-18 | Dow Pharmaceutical Sciences | Methods of treating skin conditions exhibiting telangiectasia |
| WO2013022201A1 (en) | 2011-08-11 | 2013-02-14 | Dong-A Pharm. Co., Ltd. | Process of preparing a stabilized and solubilized formulation of sirolimus derivatives |
| KR101151890B1 (ko) * | 2011-08-11 | 2012-05-31 | 동아제약주식회사 | 안정화 및 가용화된 시롤리무스 유도체 조성물의 제조방법 |
| US8912215B2 (en) * | 2011-12-13 | 2014-12-16 | Everon Biosciences, Inc. | Rapamycin composition |
-
2014
- 2014-02-14 HU HU1400075A patent/HUP1400075A2/hu unknown
-
2015
- 2015-02-13 JP JP2016569114A patent/JP6445591B2/ja not_active Expired - Fee Related
- 2015-02-13 UA UAA201609489A patent/UA120508C2/uk unknown
- 2015-02-13 AU AU2015216631A patent/AU2015216631B2/en not_active Ceased
- 2015-02-13 EP EP15710913.3A patent/EP3104844B1/en not_active Revoked
- 2015-02-13 HU HUE15710913A patent/HUE048801T2/hu unknown
- 2015-02-13 RU RU2016136697A patent/RU2016136697A/ru unknown
- 2015-02-13 WO PCT/IB2015/051086 patent/WO2015121836A1/en not_active Ceased
- 2015-02-13 ES ES15710913T patent/ES2784843T3/es active Active
- 2015-02-13 US US15/118,166 patent/US20170165237A1/en not_active Abandoned
- 2015-02-13 CN CN201580019255.5A patent/CN106456780A/zh active Pending
- 2015-02-13 CA CA2939602A patent/CA2939602A1/en not_active Abandoned
- 2015-02-13 PL PL15710913T patent/PL3104844T3/pl unknown
- 2015-02-13 HK HK17105293.4A patent/HK1231416A1/zh unknown
-
2016
- 2016-08-11 IL IL247239A patent/IL247239A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505822A5 (enExample) | ||
| Schopf et al. | Topical ocular drug delivery to the back of the eye by mucus-penetrating particles | |
| JP2016535777A5 (enExample) | ||
| RU2016136697A (ru) | Комплексы сиролимуса и его производных, способ их получения и фармацевтические композиции, содержащие указанные комплексы | |
| CN107530348B (zh) | 一种含有jak激酶抑制剂或其可药用盐的药物组合物 | |
| CN106232144B (zh) | 固体分散体 | |
| JP2015511241A5 (enExample) | ||
| WO2012116238A1 (en) | PHARMACEUTICAL FORMULATIONS OF ACETYL-11-KETO-β-BOSWELLIC ACID, DIINDOLYLMETHANE, AND CURCUMIN FOR PHARMACEUTICAL APPLICATIONS | |
| JP2018504443A5 (enExample) | ||
| RU2013122656A (ru) | Композиции и способы доставки терапевтических средств | |
| CN107847490A (zh) | 改进的地拉罗司制剂及制备其的方法 | |
| CN101631533B (zh) | 含有西洛他唑的控释制剂及其制备方法 | |
| TW201444589A (zh) | 錠劑型式 | |
| US20170368031A1 (en) | Solid dispersion formulations of antiviral compounds | |
| JP2017526697A5 (enExample) | ||
| JP2017527600A5 (enExample) | ||
| AU2016373574B2 (en) | Pharmaceutical compositions comprising phenylaminopyrimidine derivative | |
| JP2017531044A5 (enExample) | ||
| Tran et al. | Modulation of drug crystallization and molecular interactions by additives in solid dispersions for improving drug bioavailability | |
| RU2017112930A (ru) | Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза | |
| JP2015520241A5 (enExample) | ||
| JP2013504615A (ja) | 溶出率向上と副作用発現が最小化されたシルロスタゾール徐放錠 | |
| JP6843896B2 (ja) | 水性点眼点鼻用組成物 | |
| CN108012526A (zh) | 具有改进的生物利用度的含普仑司特固体制剂的组合物及其制备方法 | |
| TW202237145A (zh) | 莫奈皮拉韋的醫藥組成物 |